EGFR and dermatological toxicity: For instance, cetuximab, an EGFR-targeted medication, has been associated with severe skin toxicity, while erlotinib, a TKI targeting EGFR, inhibits the effector’s action, which leads to the development of drug resistance, and while doing so, immune checkpoint inhibitors could bring about immunological side effects (304).